
AstraZeneca's Datroway Leads in Triple-Negative Breast Cancer Treatment at ESMO
AstraZeneca and Gilead Sciences presented successful trial results for antibody-drug conjugates as new first-line treatments for metastatic triple-negative breast cancer, offering potential options after over a decade without new approvals for this aggressive cancer type.












